Sweden
· Delayed Price · Currency is SEK Bio Vitos Pharma AB Statistics
Total Valuation
STO:BIOVIT has a market cap or net worth of SEK 4.73 million. The enterprise value is 4.71 million.
| Market Cap | 4.73M |
| Enterprise Value | 4.71M |
Important Dates
The last earnings date was Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:BIOVIT has 39.40 million shares outstanding. The number of shares has increased by 609.36% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 39.40M |
| Shares Change (YoY) | +609.36% |
| Shares Change (QoQ) | +23.95% |
| Owned by Insiders (%) | 9.18% |
| Owned by Institutions (%) | 1.94% |
| Float | 17.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.51 |
| PB Ratio | 0.29 |
| P/TBV Ratio | 25.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.24 |
| EV / Sales | 11.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.39
| Current Ratio | 1.39 |
| Quick Ratio | 0.96 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -81.02% and return on invested capital (ROIC) is -45.82%.
| Return on Equity (ROE) | -81.02% |
| Return on Assets (ROA) | -44.47% |
| Return on Invested Capital (ROIC) | -45.82% |
| Return on Capital Employed (ROCE) | -111.47% |
| Revenue Per Employee | 410,627 |
| Profits Per Employee | -19.86M |
| Employee Count | 1 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.10 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.18% in the last 52 weeks. The beta is 2.15, so STO:BIOVIT's price volatility has been higher than the market average.
| Beta (5Y) | 2.15 |
| 52-Week Price Change | -95.18% |
| 50-Day Moving Average | 0.11 |
| 200-Day Moving Average | 0.95 |
| Relative Strength Index (RSI) | 51.57 |
| Average Volume (20 Days) | 1,388,786 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:BIOVIT had revenue of SEK 410,627 and -19.86 million in losses. Loss per share was -0.50.
| Revenue | 410,627 |
| Gross Profit | 362,627 |
| Operating Income | -17.98M |
| Pretax Income | -19.86M |
| Net Income | -19.86M |
| EBITDA | -3.11M |
| EBIT | -17.98M |
| Loss Per Share | -0.50 |
Balance Sheet
The company has 21,245 in cash and n/a in debt, giving a net cash position of 21,245 or 0.00 per share.
| Cash & Cash Equivalents | 21,245 |
| Total Debt | n/a |
| Net Cash | 21,245 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 16.13M |
| Book Value Per Share | 0.41 |
| Working Capital | 188,593 |
Cash Flow
| Operating Cash Flow | -2.90M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 88.31% |
| Operating Margin | -4,377.66% |
| Pretax Margin | -4,837.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
STO:BIOVIT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -609.36% |
| Shareholder Yield | -609.36% |
| Earnings Yield | -420.11% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on November 5, 2024. It was a reverse split with a ratio of 0.1.
| Last Split Date | Nov 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
STO:BIOVIT has an Altman Z-Score of 41.82.
| Altman Z-Score | 41.82 |
| Piotroski F-Score | n/a |